Evidence-based medicine (EBM) and pharmacoeconomics (PE) evaluation conference of Shenqifuzheng Injection was held in Bejing on July 10, 2012. Doctor Cao Hui from Livzon TCM center, Deputy Director Hu Haitang from Livzon R&D Institute and Doctor Huang Wenhua from R&D Institute of Livzon (Group) Limin Pharmaceutical Factory participated in the conference on behalf of Livzon Group. Other participants also included leaders and experts from Chinese Traditional Medicine Committee, Evidence-Based Medicine and Pharmacoeconomics Evaluation Committee, China Health and Economic Research Center in Peking University, Social Security Institute in Human and Social Ministry and EMB Center in Bejing University of Chinese Medicine. The vital technical point in the protocol and the implementation plan of the project were made based on the experts’ discussion and the integration of research requirements and professional and technological judgment.
As one of the strategic products of Livzon Group, the pharmacoeconomic evaluation in cancer adjuvant therapy is of strategic significance for Shenqifuzheng Injection.